Gatifloxacin ophthalmic solution is used to treat bacterial conjunctivitis (pinkeye; infection of the membrane that covers the outside of the eyeballs and the inside of the eyelids) in adults and children 1 year of age and older.
Fluoroquinolone: Antibacterial
Gatifloxacin eye drops is an 8-methoxyfluoroquinolone anti-infective for topical ophthalmic use. The antibacterial action of Gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. It appears that the C-8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of gram-positive bacteria compared to the nonmethoxy C-8 moiety.
ORAL Respiratory tract infections; Susceptible infections; Urinary tract Infections: Adult: 400 mg once daily. Uncomplicated gonorrhoea: Adult: 400 mg as a single dose. Uncomplicated urinary tract infections: Adult: 400 mg as a single dose or 200 mg daily for 3 days. INTRAVENOUS Respiratory tract infections; Susceptible infections; Urinary tract infections: Adult: 400 mg once daily, infused as a 2 mg/mI soln over 60 minutes.
Specific drug interaction studies have not been conducted with Gatifloxacin eye drops.
Hypersensitivity; child <18 yr; concurrent use of class IA or Ill antiarrhythmics, QT-prolongation drugs: diabetics; pregnancy, lactation. May prolong QT interval; uncorrected hypokalaemia; known or suspected CNS disorders, renal & hepatic impairment. Elderly.
Rapid heartbeat, mental confusion, hallucinations, agitation, nightmares, depression; photophobia; tendon rupture; headache, dizziness, insomnia, chills, fever; back pain, abdominal pain; constipation, nausea, vomiting, diarrhoea, inflammation of the tongue, mouth sores; abnormal vision, ringing in the ears, vaginitis. Hyperosmolar nonketotic hyperglycaemic coma, diabetic ketoacidosis, hypoglycaemic coma, convulsions & mental status changes.
Gatifloxacin has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of maternal toxicity, decreased fetal and placental weight, and delayed fetal skeletal ossification. There are no controlled data in human pregnancies. Because safer alternatives are generally available, some experts consider other fluoroquinolones contraindicated during pregnancy, especially during the first trimester. It is not known if gatifloxacin is excreted into human milk. However, since other fluoroquinolone antibiotics are excreted into human milk, it is likely that gatifloxacin is also. Quinolone-induced cartilage erosion and arthropathies that have been observed in juvenile animals render some concern over its possible toxic effects on the developing joints of nursing infants. Because of the potential for serious adverse effects in nursing infants, a decision should be made to discontinue nursing or discontinue administration of gatifloxacin, taking into account the importance of the drug to the mother.
An overdose of this medication is unlikely to threaten life.
Protect from light. Store in cool & dry place; keep out of the reach of children. Do not use more than 4 weeks after opening.
.png&w=384&q=75)